The DOI matches its Crossref record; 253 of the 254 references it cites were found in a registry or an index.
The Alzheimer's disease Beta-secretase enzyme, BACE1
Open accessAbstract
The pathogenesis of Alzheimer's disease is highly complex. While several pathologies characterize this disease, amyloid plaques, composed of the beta-amyloid peptide are hallmark neuropathological lesions in Alzheimer's disease brain. Indeed, a wealth of evidence suggests that beta-amyloid is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. The BACE1 enzyme is essential for the generation of beta-amyloid. BACE1 knockout mice do not produce beta-amyloid and are free from Alzheimer's associated pathologies including neuronal loss and certain memory deficits. The fact that BACE1 initiates the formation of beta-amyloid, and the observation that BACE1 levels are elevated in this disease provide direct and compelling reasons to develop therapies directed at BACE1 inhibition thus reducing beta-amyloid and its associated toxicities. However, new data indicates that complete abolishment of BACE1 may be associated with specific behavioral and physiological alterations. Recently a number of non-APP BACE1 substrates have been identified. It is plausible that failure to process certain BACE1 substrates may underlie some of the reported abnormalities in the BACE1-deficient mice. Here we review BACE1 biology, covering aspects ranging from the initial identification and characterization of this enzyme to recent data detailing the apparent dysregulation of BACE1 in Alzheimer's disease. We pay special attention to the putative function of BACE1 during healthy conditions and discuss in detail the relationship that exists between key risk factors for AD, such as vascular disease (and downstream cellular consequences), and the pathogenic alterations in BACE1 that are observed in the diseased state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The intracellular trafficking of BACE1. (1) Following synthesis in the ER, pro-BACE1 traffics to the Golgi. Here, the propeptide is removed and BACE1 undergoes significant post-translational modifications. The trafficking and localization of BACE1 appear dependent on the ACDL motif, composed of DISLL residues, in its C-terminal tail. Importantly, phosphorylation of the serine 498 residue (S498) is important for binding of BACE1 to the GGA monomeric adaptor proteins which are implicated in the sorting of cargo between the TGN and endosomes and vice versa [127-131], in addition to the Golgi complex to the endosomes [130]. (2) BACE1 traffics to the plasma membrane and while the re-internalization of BACE1 from the cell surface appears to be independent of the phosphorylation state of S498 [131], it has been reported that the di-leucine residues are important for BACE1 endocytosis [126]. Non-phosphorylated BACE1 may recycle from the endosome back to the cell surface [131]. However, BACE1 phosphorylated at the S498 site interacts with GGA1 in the endosome and traffics back to the TGN [131], and (3) the interaction of phosphorylated BACE1 with GGA3 appears to direct BACE1 to the lysosome, where it is degraded [135]. In addition to S498 phosphorylation, the di-leucine residues are also important for the sorting of BACE1 into lysosomal compartments [140]. BACE1 is also degraded in the proteasome [133]. The precise subcellular localization (early verses late endosomes) of the BACE1-GGA complex requires determination, and while it appears likely that BACE1 can traffic from the TGN to the endosome directly, it remains to be demonstrated experimentally.](https://figures.cochat.ai/paper-figures/ababb34006ec42cebddaefb7cf4bc47b/the-alzheimer-s-disease-beta-secretase-enzyme-bace1-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abnormal activation of microglia and astrocytes is observed in the brains of AD patients15 and APPPS1–21 transgenic model mice13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Activated microglia surround amyloid plaques in the brains of both human patients with AD and mouse models of Aβ amyloidosis13,15,21,22.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
2 retracted
Puglielli, L., Ellis, B. C., Saunders, A. J., & Kovacs, D. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300466200 · Cited by 265
RetractedGhribi, O., Larsen, B., Schrag, M., & Herman, M. M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.03.019 · Cited by 151
RetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“However, specific risk factors for AD have been recently identified and include aging, the presence of the apolipoprotein E4 (ApoE4) allele [5] and vascular diseases such as stroke and heart disease [6-10].”
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 9×
“However, unlike BACE1, which is enriched in neuronal populations [23], human adult and fetal whole brain express very low or undetectable levels of BACE2 mRNA [50,74].”
InfluentialSelf-citationOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3×
“5XFAD mice exhibit aggressive pathology with plaque deposition occurring at 2 months and exhibit significant neuronal loss in AD-sensitive brain regions [60].”
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Research works printed but not linked: 2
- Golde TE, Dickson D, Hutton M: Filling the gaps in the abeta cas- cade hypothesis of Alzheimer's disease. Curr Alzheimer Res 2006, 3(5):421-430.
- Hong HS, Hwang EM, Sim HJ, Cho HJ, Boo JH, Oh SS, Kim SU, Mook- Jung I: Interferon gamma stimulates beta-secretase expres- sion and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 2003, 307(4):922-927.
Cited by
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2015) · Medical Principles and Practice · doi:10.1159/000369101 · Cited by 537
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Metadata
- Authors
- Cole, S. L., & Vassar, R.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Vassar, Robert
- ORCID
- Vassar, Robert
- Venue
- Molecular Neurodegeneration
- Published
- 2007
- Volume
- 2
- Issue
- 1
- Pages
- 22
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC2211305
- OpenAlex
- W2129495914
- Cited by
- 550
- References
- 254
- Citations by year
- 2026: 27 · 2025: 53 · 2024: 45 · 2023: 46 · 2022: 27 · 2021: 40 · 2020: 32 · 2019: 30 · 2018: 20 · 2017: 25 · 2016: 31 · 2015: 25 · 2014: 27 · 2013: 27 · 2012: 23
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- John Douglas French Alzheimer's Foundation
- National Institute on Aging (P01AG021184)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, BACE1, beta-secretase, amyloid-beta, amyloid plaques, BACE1 inhibition, vascular disease, Alzheimer's disease risk factors, neurodegeneration, memory impairment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Alzheimer's disease Beta-secretase enzyme, BACE1. https://app.cochat.ai/papers/10.1186/1750-1326-2-22
- The paper
- Cole, S. L., & Vassar, R. (2007). The Alzheimer's disease Beta-secretase enzyme, BACE1. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-2-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.